{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semax-diabetic-neuropathy","title":"Semax for Diabetic Neuropathy: Evidence-Graded Review","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\n\n## Why Semax might help you\n\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\n\n## How these fit together\n\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\n\n## What the evidence actually shows\n\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\n\nPreclinical studies show Semax influences BDNF expression and provides neuroprotection in rat models of ischemia and inflammation, but none directly model diabetic neuropathy (preclinical).\n\nAnecdotal reports on clinic websites mention improvement in non-proliferative diabetic neuropathy, but these are promotional and unverified by independent trials (anecdotal).\n\n## What scientists say\n\nResearchers note Semax's ability to modulate neurotrophin expression and counteract inflammatory gene patterns in rodent brain injury models. Translation to human diabetic neuropathy lacks direct testing. One analysis highlights potential neuroprotective roles via melanocortin pathways, yet cautions on limited long-term human data (mechanistic/preclinical).\n\n## What people say on Reddit\n\nDiscussions rarely link Semax directly to diabetic neuropathy relief. Isolated mentions appear in broader peptide threads, often alongside unrelated compounds or as side-effect reports in other contexts. No consistent positive or negative anecdotes tied specifically to neuropathy symptoms (anecdotal).\n\n## What people say on X\n\nPublic posts on X show minimal discussion of Semax for diabetic neuropathy. Occasional references echo clinic claims without user-reported outcomes or long-term tracking (anecdotal/speculative).\n\n## What we do not know\n\nNo robust human trials confirm nerve regeneration or symptom change in diabetic neuropathy. Dose-response, duration, and combination effects remain unstudied for this indication. Animal data on BDNF does not prove human peripheral nerve repair.\n\n## Safety and limits\n\nReported effects in available literature include possible nasal irritation or blood glucose changes in some diabetic users, though data is sparse. Evidence base is primarily Russian-language or preclinical; Western regulatory status limits formal recommendations. Individual responses vary widely.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax has been evaluated in patients with nonproliferative diabetic neuropathy per a 2013 review reference.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Indicates limited human data exists but lacks detail on outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF and supports neural repair in preclinical models.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Grounds the repair-focused logic chain.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Clinic sites claim Semax improves non-proliferative diabetic neuropathy.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights promotional vs. rigorous evidence distinction.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large RCTs exist for Semax in diabetic neuropathy.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gaps for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pdfs.semanticscholar.org/2a11/334f12fff603f90a83ef1127e3192ca186b2.pdf","title":"A New Generation of Drugs: Synthetic Peptides Based on Regulatory Peptides","quote":"3) Nonproliferative Diabetic Neuropathy . We evaluated the efficacy of the drug “ Semax 0.1%” in the treatment of patients with nonproliferative diabetic.","summary":"Review mentions evaluation of Semax in diabetic neuropathy patients.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"f50c4ec846a6c99b2335c4ecaed83699d99f5b23ed6912c903cdff3a44291c1f"},{"id":"s2","type":"pubmed","url":"https://en.wikipedia.org/wiki/Semax","title":"Semax - Wikipedia","quote":"In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus","summary":"Summarizes animal data on BDNF.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"unverified","prev":"f50c4ec846a6c99b2335c4ecaed83699d99f5b23ed6912c903cdff3a44291c1f","hash":"e958a14f32e4cc247ede2e68063f39e8d136211ee70c80b1aa7a1540bcf904d8"},{"id":"s3","type":"other","url":"https://www.caseintegrativehealth.com/peptide-therapies/semax","title":"Semax - Case Integrative Health","quote":"It can increase attention and short-term memory, improve Non-proliferative Diabetic Neuropathy","summary":"Clinic claim on neuropathy improvement.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"verified","prev":"e958a14f32e4cc247ede2e68063f39e8d136211ee70c80b1aa7a1540bcf904d8","hash":"73a9941fe0d8c6f6ddcd518d07916b7d9479581b5adc49e95cf59cd6cbed6869"},{"id":"s4","type":"review","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Although I am unable to access the original data from published studies in humans using semax...","summary":"Notes limited accessible human data overall.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"unverified","prev":"73a9941fe0d8c6f6ddcd518d07916b7d9479581b5adc49e95cf59cd6cbed6869","hash":"5ccda41ca9f2ee7ba794c7168e718ac9d198d5027104ea28b5e75fbb15368ba0"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:12:55.220Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Diabetic Neuropathy: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\n\n## Why Semax might help you\n\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\n\n## How these fit together\n\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\n\n## What the evidence actually shows\n\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\n\nPreclinical studies show Semax influences BDNF expression and provides neuroprotection in rat models of ischemia and inflammation, but none directly model diabetic neuropathy (preclinical).\n\nAnecdotal reports on clinic websites mention improvement in non-proliferative diabetic neuropathy, but these are promotional and unverified by independent trials (anecdotal).\n\n## What scientists say\n\nResearchers note Semax's ability to modulate neurotrophin expression and counteract inflammatory gene patterns in rodent brain injury models. Translation to human diabetic neuropathy lacks direct testing. One analysis highlights potential neuroprotective roles via melanocortin pathways, yet cautions on limited long-term human data (mechanistic/preclinical).\n\n## What people say on Reddit\n\nDiscussions rarely link Semax directly to diabetic neuropathy relief. Isolated mentions appear in broader peptide threads, often alongside unrelated compounds or as side-effect reports in other contexts. No consistent positive or negative anecdotes tied specifically to neuropathy symptoms (anecdotal).\n\n## What people say on X\n\nPublic posts on X show minimal discussion of Semax for diabetic neuropathy. Occasional references echo clinic claims without user-reported outcomes or long-term tracking (anecdotal/speculative).\n\n## What we do not know\n\nNo robust human trials confirm nerve regeneration or symptom change in diabetic neuropathy. Dose-response, duration, and combination effects remain unstudied for this indication. Animal data on BDNF does not prove human peripheral nerve repair.\n\n## Safety and limits\n\nReported effects in available literature include possible nasal irritation or blood glucose changes in some diabetic users, though data is sparse. Evidence base is primarily Russian-language or preclinical; Western regulatory status limits formal recommendations. Individual responses vary widely.","claims":[{"id":"c1","text":"Semax has been evaluated in patients with nonproliferative diabetic neuropathy per a 2013 review reference.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Indicates limited human data exists but lacks detail on outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF and supports neural repair in preclinical models.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Grounds the repair-focused logic chain.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Clinic sites claim Semax improves non-proliferative diabetic neuropathy.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights promotional vs. rigorous evidence distinction.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large RCTs exist for Semax in diabetic neuropathy.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gaps for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pdfs.semanticscholar.org/2a11/334f12fff603f90a83ef1127e3192ca186b2.pdf","title":"A New Generation of Drugs: Synthetic Peptides Based on Regulatory Peptides","quote":"3) Nonproliferative Diabetic Neuropathy . We evaluated the efficacy of the drug “ Semax 0.1%” in the treatment of patients with nonproliferative diabetic.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://en.wikipedia.org/wiki/Semax","title":"Semax - Wikipedia","quote":"In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"other","url":"https://www.caseintegrativehealth.com/peptide-therapies/semax","title":"Semax - Case Integrative Health","quote":"It can increase attention and short-term memory, improve Non-proliferative Diabetic Neuropathy","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"review","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Although I am unable to access the original data from published studies in humans using semax...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":27095,"tokens_out":2836,"cost":0.04095875,"prev_hash":"genesis","hash":"c4e3fd7e2eb967d7e8832981057d279b13c9de9ccd761fa026b4c07c349fc5cf"}],"provenance":[{"ts":"2026-06-30T00:12:55.220Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Diabetic Neuropathy\nSlug: semax-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"semax\",\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n4. **Therefore for you:** If that l","response":"{\n  \"slug\": \"semax-diabetic-neuropathy\",\n  \"title\": \"Semax for Diabetic Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\\n\\n## Why Semax might help you\\n\\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\\n\\n## How these fit together\\n\\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\\n\\n## What the evidence actually shows\\n\\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\\n\\nPreclinical studies show Semax influences BDNF expressio","tokens_in":27095,"tokens_out":2836,"cost":0,"prev":"genesis","hash":"32ddc4f2e2f8cc089a3acdce0ed023f9b7c7471f05117d70564589d4631b6546"},{"ts":"2026-07-17T02:41:53.019Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-diabetic-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"32ddc4f2e2f8cc089a3acdce0ed023f9b7c7471f05117d70564589d4631b6546","hash":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"}],"energy":{"passes":2,"tokens_in":27095,"tokens_out":2836,"tokens_total":29931,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"},"posted_at":"2026-06-29T21:33:15.940Z","created_at":"2026-06-29T21:33:15.940Z","updated_at":"2026-07-17T02:41:53.019Z","machine":{"shape":"article.machine/v1","slug":"semax-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/semax-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/semax-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semax-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-diabetic-neuropathy","json":"/api/articles/semax-diabetic-neuropathy","markdown":"/api/articles/semax-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/semax-diabetic-neuropathy/skill","topology":"/api/articles/semax-diabetic-neuropathy/topology","versions":"/api/articles/semax-diabetic-neuropathy/revisions","invocations":"/api/articles/semax-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"93fa8428fe366f5f2e8a1e39114ee769983ba55e49274d706bea1a8a2331baed","object":{"object_type":"article-object","identity":{"id":"article:semax-diabetic-neuropathy","slug":"semax-diabetic-neuropathy","title":"Semax for Diabetic Neuropathy: Evidence-Graded Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semax-diabetic-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semax-diabetic-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: semax-diabetic-neuropathy\ndescription: Apply the Semax for Diabetic Neuropathy: Evidence-Graded Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Semax for Diabetic Neuropathy: Evidence-Graded Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/semax-diabetic-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semax-diabetic-neuropathy.\n- Read claims and relationships at /api/articles/semax-diabetic-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Diabetic neuropathy Diabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular\n\n## Representations\n\n- Human: /a/semax-diabetic-neuropathy\n- JSON: /api/articles/semax-diabetic-neuropathy\n- Relationships: /api/articles/semax-diabetic-neuropathy/topology\n- History: /api/articles/semax-diabetic-neuropathy/revisions\n"},"json":{"route":"/api/articles/semax-diabetic-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semax-diabetic-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","semax","diabetic","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semax-diabetic-neuropathy/invocations?status=success","failure_events":"/api/articles/semax-diabetic-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semax-diabetic-neuropathy","title":"Semax for Diabetic Neuropathy: Evidence-Graded Review","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\n\n## Why Semax might help you\n\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\n\n## How these fit together\n\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\n\n## What the evidence actually shows\n\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\n\nPreclinical studies show Semax influences BDNF expression and provides neuroprotection in rat models of ischemia and inflammation, but none directly model diabetic neuropathy (preclinical).\n\nAnecdotal reports on clinic websites mention improvement in non-proliferative diabetic neuropathy, but these are promotional and unverified by independent trials (anecdotal).\n\n## What scientists say\n\nResearchers note Semax's ability to modulate neurotrophin expression and counteract inflammatory gene patterns in rodent brain injury models. Translation to human diabetic neuropathy lacks direct testing. One analysis highlights potential neuroprotective roles via melanocortin pathways, yet cautions on limited long-term human data (mechanistic/preclinical).\n\n## What people say on Reddit\n\nDiscussions rarely link Semax directly to diabetic neuropathy relief. Isolated mentions appear in broader peptide threads, often alongside unrelated compounds or as side-effect reports in other contexts. No consistent positive or negative anecdotes tied specifically to neuropathy symptoms (anecdotal).\n\n## What people say on X\n\nPublic posts on X show minimal discussion of Semax for diabetic neuropathy. Occasional references echo clinic claims without user-reported outcomes or long-term tracking (anecdotal/speculative).\n\n## What we do not know\n\nNo robust human trials confirm nerve regeneration or symptom change in diabetic neuropathy. Dose-response, duration, and combination effects remain unstudied for this indication. Animal data on BDNF does not prove human peripheral nerve repair.\n\n## Safety and limits\n\nReported effects in available literature include possible nasal irritation or blood glucose changes in some diabetic users, though data is sparse. Evidence base is primarily Russian-language or preclinical; Western regulatory status limits formal recommendations. Individual responses vary widely.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semax-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax has been evaluated in patients with nonproliferative diabetic neuropathy per a 2013 review reference.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Indicates limited human data exists but lacks detail on outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF and supports neural repair in preclinical models.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Grounds the repair-focused logic chain.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Clinic sites claim Semax improves non-proliferative diabetic neuropathy.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights promotional vs. rigorous evidence distinction.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large RCTs exist for Semax in diabetic neuropathy.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gaps for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pdfs.semanticscholar.org/2a11/334f12fff603f90a83ef1127e3192ca186b2.pdf","title":"A New Generation of Drugs: Synthetic Peptides Based on Regulatory Peptides","quote":"3) Nonproliferative Diabetic Neuropathy . We evaluated the efficacy of the drug “ Semax 0.1%” in the treatment of patients with nonproliferative diabetic.","summary":"Review mentions evaluation of Semax in diabetic neuropathy patients.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"f50c4ec846a6c99b2335c4ecaed83699d99f5b23ed6912c903cdff3a44291c1f"},{"id":"s2","type":"pubmed","url":"https://en.wikipedia.org/wiki/Semax","title":"Semax - Wikipedia","quote":"In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus","summary":"Summarizes animal data on BDNF.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"unverified","prev":"f50c4ec846a6c99b2335c4ecaed83699d99f5b23ed6912c903cdff3a44291c1f","hash":"e958a14f32e4cc247ede2e68063f39e8d136211ee70c80b1aa7a1540bcf904d8"},{"id":"s3","type":"other","url":"https://www.caseintegrativehealth.com/peptide-therapies/semax","title":"Semax - Case Integrative Health","quote":"It can increase attention and short-term memory, improve Non-proliferative Diabetic Neuropathy","summary":"Clinic claim on neuropathy improvement.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"verified","prev":"e958a14f32e4cc247ede2e68063f39e8d136211ee70c80b1aa7a1540bcf904d8","hash":"73a9941fe0d8c6f6ddcd518d07916b7d9479581b5adc49e95cf59cd6cbed6869"},{"id":"s4","type":"review","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Although I am unable to access the original data from published studies in humans using semax...","summary":"Notes limited accessible human data overall.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:12:54.213Z","link_status":"ok","quote_status":"unverified","prev":"73a9941fe0d8c6f6ddcd518d07916b7d9479581b5adc49e95cf59cd6cbed6869","hash":"5ccda41ca9f2ee7ba794c7168e718ac9d198d5027104ea28b5e75fbb15368ba0"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:12:55.220Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Semax for Diabetic Neuropathy: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\n\n## Why Semax might help you\n\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\n\n## How these fit together\n\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\n\n## What the evidence actually shows\n\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\n\nPreclinical studies show Semax influences BDNF expression and provides neuroprotection in rat models of ischemia and inflammation, but none directly model diabetic neuropathy (preclinical).\n\nAnecdotal reports on clinic websites mention improvement in non-proliferative diabetic neuropathy, but these are promotional and unverified by independent trials (anecdotal).\n\n## What scientists say\n\nResearchers note Semax's ability to modulate neurotrophin expression and counteract inflammatory gene patterns in rodent brain injury models. Translation to human diabetic neuropathy lacks direct testing. One analysis highlights potential neuroprotective roles via melanocortin pathways, yet cautions on limited long-term human data (mechanistic/preclinical).\n\n## What people say on Reddit\n\nDiscussions rarely link Semax directly to diabetic neuropathy relief. Isolated mentions appear in broader peptide threads, often alongside unrelated compounds or as side-effect reports in other contexts. No consistent positive or negative anecdotes tied specifically to neuropathy symptoms (anecdotal).\n\n## What people say on X\n\nPublic posts on X show minimal discussion of Semax for diabetic neuropathy. Occasional references echo clinic claims without user-reported outcomes or long-term tracking (anecdotal/speculative).\n\n## What we do not know\n\nNo robust human trials confirm nerve regeneration or symptom change in diabetic neuropathy. Dose-response, duration, and combination effects remain unstudied for this indication. Animal data on BDNF does not prove human peripheral nerve repair.\n\n## Safety and limits\n\nReported effects in available literature include possible nasal irritation or blood glucose changes in some diabetic users, though data is sparse. Evidence base is primarily Russian-language or preclinical; Western regulatory status limits formal recommendations. Individual responses vary widely.","claims":[{"id":"c1","text":"Semax has been evaluated in patients with nonproliferative diabetic neuropathy per a 2013 review reference.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Indicates limited human data exists but lacks detail on outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Semax upregulates BDNF and supports neural repair in preclinical models.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Grounds the repair-focused logic chain.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Clinic sites claim Semax improves non-proliferative diabetic neuropathy.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights promotional vs. rigorous evidence distinction.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No large RCTs exist for Semax in diabetic neuropathy.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gaps for readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:12:54.669Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pdfs.semanticscholar.org/2a11/334f12fff603f90a83ef1127e3192ca186b2.pdf","title":"A New Generation of Drugs: Synthetic Peptides Based on Regulatory Peptides","quote":"3) Nonproliferative Diabetic Neuropathy . We evaluated the efficacy of the drug “ Semax 0.1%” in the treatment of patients with nonproliferative diabetic.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://en.wikipedia.org/wiki/Semax","title":"Semax - Wikipedia","quote":"In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"other","url":"https://www.caseintegrativehealth.com/peptide-therapies/semax","title":"Semax - Case Integrative Health","quote":"It can increase attention and short-term memory, improve Non-proliferative Diabetic Neuropathy","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"review","url":"https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf","title":"Semax Cognitive Vitality For Researchers","quote":"Although I am unable to access the original data from published studies in humans using semax...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":27095,"tokens_out":2836,"cost":0.04095875,"prev_hash":"genesis","hash":"c4e3fd7e2eb967d7e8832981057d279b13c9de9ccd761fa026b4c07c349fc5cf"}],"provenance":[{"ts":"2026-06-30T00:12:55.220Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Diabetic Neuropathy\nSlug: semax-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"semax\",\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n4. **Therefore for you:** If that l","response":"{\n  \"slug\": \"semax-diabetic-neuropathy\",\n  \"title\": \"Semax for Diabetic Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\\n\\n## Why Semax might help you\\n\\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\\n\\n## How these fit together\\n\\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\\n\\n## What the evidence actually shows\\n\\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\\n\\nPreclinical studies show Semax influences BDNF expressio","tokens_in":27095,"tokens_out":2836,"cost":0,"prev":"genesis","hash":"32ddc4f2e2f8cc089a3acdce0ed023f9b7c7471f05117d70564589d4631b6546"},{"ts":"2026-07-17T02:41:53.019Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-diabetic-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"32ddc4f2e2f8cc089a3acdce0ed023f9b7c7471f05117d70564589d4631b6546","hash":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"}],"energy":{"passes":2,"tokens_in":27095,"tokens_out":2836,"tokens_total":29931,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"},"posted_at":"2026-06-29T21:33:15.940Z","created_at":"2026-06-29T21:33:15.940Z","updated_at":"2026-07-17T02:41:53.019Z","machine":{"shape":"article.machine/v1","slug":"semax-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/semax-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/semax-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/semax-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/semax-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semax-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semax-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semax-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semax-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semax-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semax-diabetic-neuropathy","json":"/api/articles/semax-diabetic-neuropathy","markdown":"/api/articles/semax-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/semax-diabetic-neuropathy/skill","topology":"/api/articles/semax-diabetic-neuropathy/topology","versions":"/api/articles/semax-diabetic-neuropathy/revisions","invocations":"/api/articles/semax-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semax-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"93fa8428fe366f5f2e8a1e39114ee769983ba55e49274d706bea1a8a2331baed"}}}